- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
PPAR Research
Volume 2012 (2012), Article ID 304760, 23 pages
doi:10.1155/2012/304760
PPARs: Interference with Warburg’ Effect and Clinical Anticancer Trials
1Inserm, HMNO, CBP, CHRU Lille, 59037 Lille, France
2Biochemistry and Molecular Biology, HMNO, CBP, CHRU Lille, 59037 Lille, France
3Department of Human Biology and Toxicology, Faculty of Medicine and Pharmacy, UMons, 7000 Mons, Belgium
4Organic Chemistry Laboratory, Faculty of Sciences, UMons, 7000 Mons, Belgium
5Inserm U1065, IFR 50, Mediterranean Center of Molecular Medicine, 06204 Nice, France
Received 14 December 2011; Revised 15 February 2012; Accepted 19 February 2012
Academic Editor: Dipak Panigrahy
Copyright © 2012 Joseph Vamecq et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to Cite this Article
Joseph Vamecq, Jean-Marie Colet, Jean Jacques Vanden Eynde, Gilbert Briand, Nicole Porchet, and Stéphane Rocchi, “PPARs: Interference with Warburg’ Effect and Clinical Anticancer Trials,” PPAR Research, vol. 2012, Article ID 304760, 23 pages, 2012. doi:10.1155/2012/304760